Systematic assessment of cervical cancer initiation and progression uncovers genetic panels for deep learning-based early diagnosis and proposes novel diagnostic and prognostic biomarkers.

Journal: Oncotarget
Published Date:

Abstract

Although many outstanding achievements in the management of cervical cancer (CxCa) have obtained, it still imposes a major burden which has prompted scientists to discover and validate new CxCa biomarkers to improve the diagnostic and prognostic assessment of CxCa. In this study, eight different gene expression data sets containing 202 cancer, 115 cervical intraepithelial neoplasia (CIN), and 105 normal samples were utilized for an integrative systems biology assessment in a multi-stage carcinogenesis manner. Deep learning-based diagnostic models were established based on the genetic panels of intrinsic genes of cervical carcinogenesis as well as on the unbiased variable selection approach. Survival analysis was also conducted to explore the potential biomarker candidates for prognostic assessment. Our results showed that cell cycle, RNA transport, mRNA surveillance, and one carbon pool by folate were the key regulatory mechanisms involved in the initiation, progression, and metastasis of CxCa. Various genetic panels combined with machine learning algorithms successfully differentiated CxCa from CIN and normalcy in cross-study normalized data sets. In particular, the 168-gene deep learning model for the differentiation of cancer from normalcy achieved an externally validated accuracy of 97.96% (99.01% sensitivity and 95.65% specificity). Survival analysis revealed that ZNF281 and EPHB6 were the two most promising prognostic genetic markers for CxCa among others. Our findings open new opportunities to enhance current understanding of the characteristics of CxCa pathobiology. In addition, the combination of transcriptomics-based signatures and deep learning classification may become an important approach to improve CxCa diagnosis and management in clinical practice.

Authors

  • Nguyen Phuoc Long
    Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Busan, 47392, Republic of Korea.
  • Kyung Hee Jung
    Department of Drug Development, College of Medicine, Inha University, Incheon 22212, Korea.
  • Sang Jun Yoon
    College of Pharmacy, Seoul National University, Seoul 08826, Korea.
  • Nguyen Hoang Anh
    School of Medicine, Vietnam National University, Ho Chi Minh 70000, Vietnam.
  • Tran Diem Nghi
    School of Medicine, Vietnam National University, Ho Chi Minh 70000, Vietnam.
  • Yun Pyo Kang
    College of Pharmacy, Seoul National University, Seoul 08826, Korea.
  • Hong Hua Yan
    Department of Drug Development, College of Medicine, Inha University, Incheon 22212, Korea.
  • Jung Eun Min
    College of Pharmacy, Seoul National University, Seoul 08826, Korea.
  • Soon-Sun Hong
    Department of Drug Development, College of Medicine, Inha University, Incheon 22212, Korea.
  • Sung Won Kwon
    College of Pharmacy, Seoul National University, Seoul 08826, Korea.

Keywords

No keywords available for this article.